By the conclusion of this video, you'll be able to describe
metabolic stability assays. You will be able to outline
how clearance can be predicted from the results
of stability assays. Finally, you'll be able to connect how the
metabolic stability of a compound can affect its
dose size and frequency. Drug metabolism
constitutes one of the most important drug
clearance pathways in vivo. As such, newly synthesized
drug molecules are screened for their
metabolic stability in dedicated biochemical assays to ensure sufficient
concentrations of an administered drug
can be maintained in vivo to effectively engage
the biological target. Drug metabolizing enzymes
can be classified as Phase I and Phase II. Phase I enzymes catalyze
reactions such as oxidation, reduction, and hydrolysis. Whereas Phase II enzymes catalyze conjugation-type
reactions. Of all the possible
biotransformation that can occur in vivo, hepatic oxidative
metabolism catalyzed by cytochrome P450
enzymes constitutes greater than 50% of the metabolic clearance
of marketed drugs. In vitro assays to assess
metabolic stability of new drug molecules are
performed to identify molecules with sufficient
stability to progress. In these assays, compounds
at a single concentration, usually one micromolar are incubated with liver microsomes
and enzyme cofactors, for example, NADPH
for cytochrome P450. The rate at which
the drug molecule is metabolized is monitored
by measuring the loss of parent drug over time
to estimate an apparent in vitro microsomal intrinsic
drug clearance value. Extrapolating the in vitro apparent microsomal
intrinsic clearance to estimate in vivo hepatic clearance
requires multiple steps. The units of in vitro apparent clearance
are microliters of the incubation cleared
of the drug per minute per milligram
of microsomal protein. Several scaling factors, which are species-specific account for the amount of
microsomal protein used in the stability assay
per gram of liver and the weight of liver in grams
per kilogram of body weight. Incorporating these
scaling factors yields the scaled microsomal
intrinsic clearance in units of milliliters per
minute per kilogram. Since metabolism
requires a delivery of the unbound
drug to the liver, the liver blood flow in units of milliliters per minute per kilogram is used to derive the in vivo hepatic
clearance value. The value is calculated using the hepatic clearance equation
shown to the lower left. Q represents the species-specific
blood flow value, F_u is the fraction of the drug that is
unbound in the plasma, and CL_int is the scaled microsomal
intrinsic clearance value. The hepatic clearance
can also be estimated with assays using other liver
subcellular fractions or isolated hepatocytes. These assays include
not only the Phase I, but also the Phase II enzymes
and hence may provide additional insights from a
biotransformation standpoint. When determining whether
the metabolic stability of a drug is acceptable, we have to consider its impact
on the efficacious dose. Metabolic stability of a
molecule affects its clearance, which impacts dose
size and frequency. For an oral drug, other factors such as
solubility and permeability are also important for oral absorption and
therefore exposure. Hence, a balance of these
properties must be considered. Additionally, potency and
volume of distribution should also be taken into
account when deciding if the molecule has an acceptable
metabolic clearance. For molecules with very high in vitro intrinsic clearance, it is also important to
understand the sites on the molecule where
metabolism occurs. Such an investigation is done by identifying metabolic
soft spots in the molecule or ascertaining the metabolites arising
from drug metabolism. This understanding
can help influence the design and
optimization of molecules. We have now covered the use of metabolic stability
assays to determine apparent intrinsic
clearance and in vitro metabolism
estimate that can be used to predict
hepatic clearance. Understanding a
molecules clearance gives the drug-hunting
team insight into how a compound may be dose to achieve efficacious
exposure in patients.